Home > Research > Publications & Outputs > TDP-43 protein in plasma may index TDP-43 brain...

Research

Links

Text available via DOI:

Keywords

View graph of relations

TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. / Foulds, Penelope; McAuley, Erica; Gibbons, Linda et al.
In: Acta Neuropathologica, Vol. 116, No. 2, 2008, p. 141-146.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Foulds, P, McAuley, E, Gibbons, L, Davidson, Y, Pickering-Brown, SM, Neary, D, Snowden, JS, Allsop, D & Mann, DMA 2008, 'TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration', Acta Neuropathologica, vol. 116, no. 2, pp. 141-146. https://doi.org/10.1007/s00401-008-0389-8

APA

Foulds, P., McAuley, E., Gibbons, L., Davidson, Y., Pickering-Brown, S. M., Neary, D., Snowden, J. S., Allsop, D., & Mann, D. M. A. (2008). TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. Acta Neuropathologica, 116(2), 141-146. https://doi.org/10.1007/s00401-008-0389-8

Vancouver

Foulds P, McAuley E, Gibbons L, Davidson Y, Pickering-Brown SM, Neary D et al. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. Acta Neuropathologica. 2008;116(2):141-146. doi: 10.1007/s00401-008-0389-8

Author

Foulds, Penelope ; McAuley, Erica ; Gibbons, Linda et al. / TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. In: Acta Neuropathologica. 2008 ; Vol. 116, No. 2. pp. 141-146.

Bibtex

@article{f1c67dff8f934c54b0b0a19cb5fb309a,
title = "TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration",
abstract = "Autopsy studies have shown that about 55% of patients with frontotemporal lobar degeneration (FTLD) and 25% of patients with Alzheimer's disease (AD) harbour TDP-43 immunoreactive pathological changes in their brains. Using ELISA, we investigated whether we could detect the presence, or increased amounts, of TDP-43 in plasma of patients with FTLD and AD compared to normal control subjects. We detected elevated levels of TDP-43 protein in plasma of 46% patients with FTLD with clinical frontotemporal dementia (FTD) and 22% patients with AD, compared to 8% of control subjects. The proportions of patients with FTD and AD showing raised plasma TDP-43 levels correspond closely to those proportions known from autopsy studies to contain TDP-43 pathological changes in their brains. Raised TDP-43 plasma levels may thereby index TDP-43 pathology within the brain. Plasma TDP-43 levels may be a biomarker that can provide a laboratory test capable of identifying the presence of TDP-43 brain pathology in neurodegenerative disease during life. It may help to distinguish those cases of FTLD with ubiquitin/TDP-43 pathology in their brains from those with tauopathy. As a predictive test, plasma TDP-43 level may have great practical value in directing therapeutic strategies aimed at preventing or removing tau or TDP-43 pathological changes from the brain in FTLD and AD.",
keywords = "Adult, Aged, Alzheimer Disease, Biological Markers, Brain, DNA-Binding Proteins, Dementia, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoprecipitation, Male, Middle Aged",
author = "Penelope Foulds and Erica McAuley and Linda Gibbons and Yvonne Davidson and Pickering-Brown, {Stuart M} and David Neary and Snowden, {Julie S} and David Allsop and Mann, {David M A}",
year = "2008",
doi = "10.1007/s00401-008-0389-8",
language = "English",
volume = "116",
pages = "141--146",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "2",

}

RIS

TY - JOUR

T1 - TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration

AU - Foulds, Penelope

AU - McAuley, Erica

AU - Gibbons, Linda

AU - Davidson, Yvonne

AU - Pickering-Brown, Stuart M

AU - Neary, David

AU - Snowden, Julie S

AU - Allsop, David

AU - Mann, David M A

PY - 2008

Y1 - 2008

N2 - Autopsy studies have shown that about 55% of patients with frontotemporal lobar degeneration (FTLD) and 25% of patients with Alzheimer's disease (AD) harbour TDP-43 immunoreactive pathological changes in their brains. Using ELISA, we investigated whether we could detect the presence, or increased amounts, of TDP-43 in plasma of patients with FTLD and AD compared to normal control subjects. We detected elevated levels of TDP-43 protein in plasma of 46% patients with FTLD with clinical frontotemporal dementia (FTD) and 22% patients with AD, compared to 8% of control subjects. The proportions of patients with FTD and AD showing raised plasma TDP-43 levels correspond closely to those proportions known from autopsy studies to contain TDP-43 pathological changes in their brains. Raised TDP-43 plasma levels may thereby index TDP-43 pathology within the brain. Plasma TDP-43 levels may be a biomarker that can provide a laboratory test capable of identifying the presence of TDP-43 brain pathology in neurodegenerative disease during life. It may help to distinguish those cases of FTLD with ubiquitin/TDP-43 pathology in their brains from those with tauopathy. As a predictive test, plasma TDP-43 level may have great practical value in directing therapeutic strategies aimed at preventing or removing tau or TDP-43 pathological changes from the brain in FTLD and AD.

AB - Autopsy studies have shown that about 55% of patients with frontotemporal lobar degeneration (FTLD) and 25% of patients with Alzheimer's disease (AD) harbour TDP-43 immunoreactive pathological changes in their brains. Using ELISA, we investigated whether we could detect the presence, or increased amounts, of TDP-43 in plasma of patients with FTLD and AD compared to normal control subjects. We detected elevated levels of TDP-43 protein in plasma of 46% patients with FTLD with clinical frontotemporal dementia (FTD) and 22% patients with AD, compared to 8% of control subjects. The proportions of patients with FTD and AD showing raised plasma TDP-43 levels correspond closely to those proportions known from autopsy studies to contain TDP-43 pathological changes in their brains. Raised TDP-43 plasma levels may thereby index TDP-43 pathology within the brain. Plasma TDP-43 levels may be a biomarker that can provide a laboratory test capable of identifying the presence of TDP-43 brain pathology in neurodegenerative disease during life. It may help to distinguish those cases of FTLD with ubiquitin/TDP-43 pathology in their brains from those with tauopathy. As a predictive test, plasma TDP-43 level may have great practical value in directing therapeutic strategies aimed at preventing or removing tau or TDP-43 pathological changes from the brain in FTLD and AD.

KW - Adult

KW - Aged

KW - Alzheimer Disease

KW - Biological Markers

KW - Brain

KW - DNA-Binding Proteins

KW - Dementia

KW - Enzyme-Linked Immunosorbent Assay

KW - Female

KW - Humans

KW - Immunoprecipitation

KW - Male

KW - Middle Aged

U2 - 10.1007/s00401-008-0389-8

DO - 10.1007/s00401-008-0389-8

M3 - Journal article

C2 - 18506455

VL - 116

SP - 141

EP - 146

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 2

ER -